

SUPPLEMENTARY TABLE 3 Individual patient laboratory and radiology investigations

Case #	Age, y; sex (†, deceased) (A, ARDS)	Leu [G/L] (4.0-10.0)	Lymph [G/L] (1.0-1.9)	Platelets [G/L] (150-400)	Hb [g/dL] (11.2-15.7)	LDH [U/L] (<250)	D-Dim [ng/mL] (<500)	CRP [mg/L] (<5)	PCT [ng/mL] (<0.5)	GFR: baseline; worst; post	Urine	Imaging (time point, day)	Imaging findings, type (distribution)	CoV-RADS; grade §
Kidney transplant with COVID-19 (KTX-COVID)														
1	52; m	-	-	-	-	-	-	-	-	68; n/a; 68	\$	-	-	-
2	55; m	11.0	-	287.0	13.9	225	-	1.3	-	65; 65; 65	P0, E0	-	-	-
3	64; f	8.5	2.35	200	12.6	224	-	0.4	-	40; 40; 40	P0, E0	-	-	-
4	68; m (A)	12.6	0.44	173	12.7	313	476	68	0.18	20; 7; 20	P0, E1	XR (1)	airspace opacification (periph, basal, bilat)	-
5	62; f (†) (A)	7.9	0.33	142	11.5	413	1236	48	0.34	15; 7 →RRT	\$	CT (8)	focal ground glass opacities (periph, bilat)	4; 2
6	62; f (†) (A)	9.4	0.15	282	10.2	258	1711	112	0.30	24; 21 →RRT	P1, E1	CT (2)	focal ground glass opacities and consolidations, crazy paving (periph, basal, bilat)	5; 3
7	69; m (†) (A)	3.4	0.24	223	10.9	602	1347	90	2.11	60; 19 →RRT	P1, E3	CT (12) and XR (10)	diffuse ground glass opacities, focal consolidations, crazy paving (bilat)	4; 4
Median (IQR)		8.9 (6.8-11.4)	0.33 (0.19-1.40)	212 (165-283)	12.1 (10.7-13.0)	285 (225-460)	1292 (666-1620)	58 (1.1-95)	0.32 (0.21-1.67)	-	-	-	-	-
Hemodialysis with COVID-19 (HD-COVID)														
1	65; m	6.9	-	358	12.5	-	-	9	-	RRT	-	-	-	-
2	79; f	4.1	0.30	163	12.4	256	3460	77	1.39	RRT	-	-	-	-
3	61; f	2.0	0.20	128	10.8	264	220	20	0.31	RRT	-	-	-	-
4	69; m	3.6	1.30	142	11.6	141	15800	9	1.05	RRT	-	-	-	-
5	73; m	4.3	0.50	166	11.5	153	390	5	0.20	RRT	-	-	-	-
6	79; f	3.9	-	210	12.1	-	-	21	-	RRT	-	-	-	-
7	38; f	5.1	0.91	156	13.1	368	5000	174	0.25	RRT	-	XR (4)	airspace opacification (periph, basal, bilat)	-
8	73; m	8.5	0.90	215	12.5	-	-	-	-	RRT	-	XR (4)	normal	-
9	66; f (A)	2.8	0.72	213	9.6	444	1402	317	5.90	RRT	P0, E0	XR (5)	airspace opacification (central, periph)	-
10	72; m (†) (A)	4.5	0.39	91	14.7	288	-	151	-	RRT	-	XR (1)	airspace opacification (periph, basal, bilat)	-
11	67; f (†) (A)	7.5	0.50	186	11.0	394	1900	189	2.83	RRT	P0, E1	CT (13) and XR (5)	focal consolidations, ground glass opacities, interlobular septal thickening (bilat, periph)	3; 3
Median (IQR)		4.3 (3.6-6.9)	0.50 (0.34-0.91)	166 (142-213)	12.1 (11.0-12.5)	276 (178-388)	1900 (390-5000)	49 (9-178)	1.10 (0.25-2.83)	-	-	-	-	-
Hemodialysis asymptomatic SARS CoV-2 RNA positive (HD-asympt CoV-2)														
1	65; f	-	-	-	-	-	-	-	-	RRT	-	-	-	-
2	79; m	3.7	-	129	12.2	-	-	3	-	RRT	-	-	-	-
3	87; f	6.9	-	183	10.8	-	-	2	-	RRT	-	-	-	-
Median (IQR)		5.3 (3.7-6.9)	-	156 (129-183)	11.5 (10.8-12.2)	-	-	2.5 (2-3)	-	-	-	-	-	-

A, ARDS, acute respiratory distress syndrome; bilat., bilateral; CRP, C-reactive protein; CT, computed tomography; CXR, chest x-ray; D-Dim, D-dimer levels; E, erythrocytes on dipstick graded 0-4; f, female; G, giga; GFR, glomerular filtration rate in ml/min/1.73m²; g, gram; Hb, hemoglobin concentration; IQR, interquartile range; L, liter; LDH, lactate dehydrogenase; Leu, leukocytes; Lymph, lymphocytes; m, male; m, milli; n, nano; P, proteinuria on dipstick graded 0-4; PCT, procalcitonin; periph., peripheral; RRT, renal replacement therapy; U, units; y, year; † deceased; \$ pre-existing proteinuria and hematuria

§ Radiologic classification, CT-score: CoV-RADS 1: no pathological findings or non-infectious abnormalities; CoV-RADS 2: pneumonia, findings inconsistent with COVID-19; CoV-RADS 3: atypical pneumonia, COVID-19 possible; CoV-RADS 4: atypical pneumonia, with signs suspicious of COVID-19 involvement; CoV-RADS 5: atypical pneumonia, with typical signs suspicious of COVID-19. Grade: the degree of involvement was graded from 0 to 4 as follows. None=0 (0%), minimal=1 (1 - 25%), mild=2 (26 - 50%), moderate=3 (51 - 75%), or severe=4 (76 - 100%)

Timepoints are expressed as days from beginning of the illness/SARS CoV-2 positivity, whichever first